文献速递其他结缔组织病

系统性硬化症重叠综合征与非重叠综合征临床特征相似但预后和治疗不同

Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments.
PubMed 文献 · Semin Arthritis Rheum · 2020-12-18

这项双中心回顾性观察研究筛查了534例系统性硬化症(SSc)患者中的重叠自身免疫病,发现34例(6.4%)为重叠SSc,其中类风湿关节炎(RA)21例、干燥综合征(SgS)14例、系统性红斑狼疮(SLE)4例。重叠SSc与非重叠SSc在皮肤表型、肺动脉高压、间质性肺病、指端溃疡和死亡率方面相似,但合并SgS与死亡率显著相关,且重叠SSc更常接受糖皮质激素、免疫抑制剂和生物制剂治疗。

要点

  • 534例SSc中重叠SSc占6.4%,以RA(3.9%)和SgS(2.6%)为主。
  • 合并SgS与死亡率显著相关(HR=3.79,95%CI 1.38-10.40)。
  • 重叠SSc更常使用激素、免疫抑制剂和生物制剂。

核心结论

  • 重叠与非重叠SSc共享临床特征,但合并SgS的SSc患者死亡风险更高。
  • 合并RA的SSc患者接受更多糖皮质激素、甲氨蝶呤和生物制剂。
  • 应推广筛查SSc相关自身免疫病,因其可能影响预后和治疗。

研究设计与样本

  • 双中心回顾性观察研究,纳入534例根据2013年ACR-EULAR分类标准诊断的SSc患者。
  • 筛查合并RA、SgS和SLE,并与非重叠SSc队列比较特征。

主要发现

  • 34例(6.4%)为重叠SSc:RA 21例(3.9%)、SgS 14例(2.6%)、SLE 4例(0.7%),5例有2种自身免疫病。
  • 重叠与非重叠SSc在皮肤表型、肺动脉高压、间质性肺病、指端溃疡和死亡率方面相似。
  • 多变量Cox模型显示年龄(HR=1.04,95%CI 1.02-1.07)、改良Rodnan皮肤评分(每点HR=1.08,95%CI 1.05-1.11)和合并SgS(HR=3.79,95%CI 1.38-10.40)与死亡率显著相关。
  • 重叠SSc更常接受糖皮质激素(85.3% vs 45%,p<0.001)、免疫抑制剂(82.4% vs 49.2%,p<0.001)和生物制剂(52.9% vs 3.8%,p<0.001)。

关键数值与推荐

  • SSc诊断依据2013年ACR-EULAR硬皮病分类标准。
  • 合并SgS与死亡率关联的HR=3.79(95%CI 1.38-10.40)。
  • 年龄与死亡率关联的HR=1.04(95%CI 1.02-1.07)。
  • 改良Rodnan皮肤评分每点与死亡率关联的HR=1.08(95%CI 1.05-1.11)。

临床怎么用

  • 对SSc患者应筛查合并RA、SgS和SLE,因其可能影响预后和治疗选择。
  • 合并SgS的SSc患者死亡风险更高,需加强监测。
  • 合并RA的SSc患者更常使用激素、甲氨蝶呤和生物制剂,治疗决策需考虑重叠疾病。

局限性

  • 回顾性观察研究设计。
  • 仅两中心数据。
  • 摘要未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To screen for concomitant autoimmune disease in patients with systemic sclerosis (overlap SSc) and to describe their clinical characteristics and prognosis. METHODS: This was a two-center retrospective observational study. Patients diagnosed with SSc according to the 2013 ACR-EULAR scleroderma classification criteria were screened for concomitant rheumatoid arthritis (RA), Sjögren syndrome (SgS) and systemic lupus erythematosus (SLE). Patient characteristics were retrieved from the medical records and were compared to those of a non-overlap SSc cohort. RESULTS: Among the 534 SSc patients studied, thirty-four (6.4%) were identified as having overlap SSc. There were 21 (3.9%) patients with RA, 14 (2.6%) with SgS and 4 (0.7%) with SLE (5 patients had 2 AISD) . The disease phenotype of overlap SSc was similar to that of non-overlap SSc in terms of cutaneous phenotype, prevalence of pulmonary arterial hypertension, interstitial lung disease, digital ulcers and mortality. Using a multivariate Cox model, age (HR = 1.04, 95% CI [1.02-1.07]), the modified Rodnan skin score (HR = 1.08 per point, 95% CI [1.05-1.11]), and the presence of concomitant SgS (HR = 3.79, 95% CI [1.38-10.40]) were significantly associated with mortality. Overlap SSc were more likely to receive corticosteroids (85.3% vs. 45%, p < 0.001), immunosuppressive drugs (82.4% vs. 49.2%, p < 0.001) and biologics (52.9% vs. 3.8%, p < ZZ0.001). CONCLUSIONS: While overlap and non-overlap SSc shared common characteristics, patients with SgS/SSc had a higher risk of mortality, and those with RA/SSc received more corticosteroids, methotrexate and biologics. Screening for an associated AISD should be promoted since their co-occurrence with SSc may affect prognosis and treatments.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Scherlinger M, Lutz J, Galli G, et al. Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments. Semin Arthritis Rheum. 2020. PMID: 33360228. doi:10.1016/j.semarthrit.2020.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。